marked.bio

BET bromodomain inhibitor · small molecule

ZEN-3694

3 active trials across 4 of our biomarkers, targeting BET. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 2 2 Phase 1
KRAS G12C 2 2 Phase 2
KRAS G12D 2 2 Phase 2
BRCA1/2 mutation 1 1 Phase 2

Trials

3 of 3 trials shown

  1. Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2022Primary completion 2026-12 NCT05327010

    ZEN-3694talazoparib

    Patients in Cohort 4 must have KRAS mutated advanced solid tumors.

    KRAS G12CKRAS G12DBRCA1/2 mutationAdvanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm

  2. Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

    Recruiting Phase 1 National Cancer Institute (NCI) Started 2024Primary completion 2027-01 NCT06102902

    ZEN-3694cetuximab FDA EUencorafenib FDA EU

    …confirmed and radiographically measurable metastatic colorectal adenocarcinoma with known BRAF V600E mutation, confirmed in a Clinical Laboratory Improvement Amendments (CLIA) certified labo…

    BRAF V600EMetastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8

  3. Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

    Recruiting Phase 1 National Cancer Institute (NCI) Started 2022Primary completion 2027-03 NCT05111561

    ZEN-3694binimetinib

    Solid tumor with genomic alteration(s) activating RAS signaling including activating KRAS, NRAS, HRAS, or BRAF mutations, inactivating NF1 mutations, or BRAF fusions

    KRAS G12CKRAS G12DBRAF V600EAdvanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma